105-57-7

Applied Filters:

Keyword:'105-57-7'

Showing 61-90 of 250 results for "105-57-7" within Technical Documents

Out 60 seconds Bead Set Customizable 7-Plex Beads IGFBP-1 19 IGFBP-2 22 IGFBP-3 72 IGFBP-4 37 IGFBP-5 55 IGFBP-6 57 IGFBP-7

Product Information Sheet-xtg360-ro

well) 9.6 2,500 250 6.8 7.5 10-cm dish 59 15,500 1,500 42.5 45 T-75 flask 75 19,700 1,900 54 57 Additional information • As with any experiment, include appropriate controls. Prepare culture

Building blocks for peptide synthesis

the glutamyl side chains can be prevented by using the low-high cleavage procedure of Tam, et al. [57]. Related products 853045 Boc-Asp(OBzl)-OH 853105 Boc-D-Asp(OBzl)-OH 853030 Boc-Asp(OcHx)-OH

hHCN1-HEK293 Recombinant Cell Line

reports. For example Altomare et al., 2003 reported a value of around 200 ms at -105 mV, Chen et al., around 300 ms at -105 mV and Moroni et al., 2001 around 322 ms at -95 mV. These values

Stem Cell and Specialty Cell Culture Product Guide

isolation and growth) CnT-57 PCT Epidermal Keratinocyte Medium, defined (for 2D isolation and growth) CnT-07 Human Epidermal Keratinocyte Progenitors, pooled donor, >5 x 105 cells HPEKP.05 Human

Protocol: Human Ghrelin (Active)

Expected pg/mL % of Expected 1 20 µL 325 100% 239 100% 10 µL 170 105% 144 95% 5 µL 90 111%

User Guide - Milli-Q Direct 8/16

........ 57 General information ............................................................................................................................................................. 57 Description

Protocol- EZHS100B-33K

- 25 56 51.6 92 74 105 95.4 91 222 253 227 90 4 0 39.4 39.4 - 25 64 61.2 95 74 113 106.8 94

Calbiochem Biologics 30.2

CORRECTIONS 11.10.04.indd Sec2:16CORRECTIONS 11.10.04.indd Sec2:16 11/10/04 12:11:57 PM11/10/04 12:11:57 PM 17 ELISA: Enzyme-linked immunosorbent assay; IB: immunoblotting; IF: immunofluorescence

Advanced Applications of Engineered Nanomaterials

oxide 25-30 nanopowder 5��7�0 Zirconium(IV) oxide 7�0 41 Nb Niobium 99+ % 100 nanopowder 59��57 42 Mo Molybdenum, activated

Protocol- HTH17MAG-14K, HT17MG-14K-PX2, HT17MAG14PMX25BK

HIL4-MAG Anti-Human IL-23 54 HIL23-MAG Anti-Human IL-5 55 HIL5-MAG Anti-Human IL-6 57 HCYIL6-MAG Anti-Human IL-17E/IL-25 66 HIL17E-MAG Anti-Human IL-27 72

Protocol: Human Th17 Magnetic Bead Panel

Anti-Human IL-23 54 ✔ HIL23-MAG ✔ Anti-Human IL-5 55 ✔ HIL5-MAG ✔ Anti-Human IL-6 57 ✔ HCYIL6-MAG ✔ Anti-Human IL-17E/IL-25 66 ✔ HIL17E-MAG ✔

Protocol- EZGRA-88K|EZGRA-88BK

mL % of Expected pg/mL % of Expected 1 20 µL 325 100% 239 100% 10 µL 170 105% 144 95% 5 µL 90 111% 57 95% 2

Antibody SourceBook, Sixth Edition, DIST version

µl €381 Anti-Serotonin 3 (5-HT3) Receptor (��-�57) Rabbit pAb FS; NOT IB mouse, rat PC3�7 25 µg €338 Anti-Serotonin 3 (5-HT3) Receptor (��-�57) Rabbit pAb FS; NOT IB mouse, rat PC3�7T 5 µg €77

Product Information - CSAA1

/d n/d 104 Cytokeratin pep.19 C6930 Cytoskeleton M y n/d n/d 105 Cytokeratin pep.4 C5176 Cytoskeleton M y n/d n/d 106 Cytokeratin pep.7 C6417 Cytoskeleton M y n/d n/d 107 Cytokeratin pep.8.13

Product Information Sheet - CSTZFN

al. Self-formation of functional adenohypophysis in three-dimensional culture. Nature, 480(7375), 57-62 (2011). B. ZFN mRNA Production The following protocols are intended for CompoZr ZFN users to

Protocol: GyroMark™ HT Human Insulin Gyros GyrolabTM xP Workstation Assay

well. 2. Label 7 polypropylene microfuge tubes as Tubes 1-7. Add 90 µL of the above prepared Serum Matrix solution to tube 7. Add 10 µL of the reconstituted standard to tube 7 and mix

Cytochrome C Assay

.g., collagen I for HepG2) to enhance cell adhesion. Adjust cell density to 5-7 x 104 cells/mL (Hela/A549) or 1-2 x 105 cells/mL (HepG2) in growth media. Add 90 µL of this cell suspension to each well

An Update on Ligands for Prostanoid Receptors

meta-benzene ring inserted between C1 and C5 [73]; it behaves as a partial agonist at the IP receptor [57]. Early work on the EP series of TP antagonists showed that a diphenylmethoxime moiety in the ω-

141464 Parteck MXP

distribution Batch Dv10 (µm) Dv25 (µm) Dv50 (µm) Dv75 (µm) Dv90 (µm) 1 20 39 65 102 150 2 15 31 57 93 141 3 17 35 61 97 145 Hygroscopicity (Dynamic vapor sorption, DVS)

141464 Parteck®MXP. Technical Information.

distribution Batch Dv10 (µm) Dv25 (µm) Dv50 (µm) Dv75 (µm) Dv90 (µm) 1 20 39 65 102 150 2 15 31 57 93 141 3 17 35 61 97 145 Hygroscopicity (Dynamic vapor sorption, DVS)

Accu-Jet Pro Pipette Controller Manual

sécutité 52 Fonction et limites d'emploi 54 Eléments de commande 56 Premiers pas 57 Mis en service 57 Support mural · rangement sur table 58 Fonctions de pipetage 59 Pipetage 60 Recharge

HUMAN INSULIN SPECIFIC RIA KIT

3 100 µl 62 62 100 75 µl 59 95 50 µl 57 92 25 µl 55 89 4

Product Information Sheet - LUCASSYRO

.... 7 Luciferase Assay Reagent 7 Lysis Buffer 7 6. General Recommendations..................................................................................................................7 Lysis

Quantitative determination of total coliforms and Escherichia coli in marine waters with chromogenic and fluorogenic media

1.1 × 104 Site M2 MTF 7 3.7 × 103 5.6 × 103 2.3 × 102 1.6 × 104 LMX 7 7.1 × 103 1.0 × 104 1.1 × 103 3.0 × 104 CC 7 3.8 × 103

Quality products, quality processes. Your guide to our chemicals for biopharmaceutical production.

86 Fr 87 Ra 88 Rf 104 Db 105 Sq 106 Bh 107 H s 108 M t 109 Ds 110 Rg 111 Cn 112 113 114 115 116 117 118 1 1 2 3 4

Protein Tyrosine Phosphatases- Potential Roles in Disease

al., Immunol. Lett., 57, 101-103 (1997). 55. Hundt, M. and Schmidt, R.E., Eur. J. Immunol., 27, 3532-3535 (1997). 56. Tangye, S.G., et al., J. Immunol., 161, 3249-3255 (1998). 57. Tangye, S.G., et al.

Inhibitor Sourcebook 3rd Edition

....... 57, 211 W-13, Hydrochloride .......................................................... 57, 211 W-5, Hydrochloride ............................................................ 57, 211 W-7, Hydrochloride

PureFlex™ and PureFlex™ Plus White Paper

none none none 1N NaOH yes Unknown (TIC) N/A 25.3 20% EtOH yes 1,1-diethoxy ethane (TIC) 105-57-7 13.9 Unknown (TIC) N/A 36.8 4-hydroxy-4-methyl-2-pentanone (TIC) 123-42-2 12.3 2-4-di-tertairy

White Paper: New Opportunities for Oral Sustained Release Formulations with Polyvinyl Alcohol

force [N] 200 800 600 400 200 100 0 0 Compression force [kN] 57 131 181 Figure 7. Tablet hardness and ejection force of propranolol-Parteck® SRP 80

Page 3 of 9